Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: Pooled analysis of phase 1 and phase 2 trials
{{output}}
Background: Therapeutic options after progression on EGFR tyrosine kinase inhibitors (TKIs) remain limited for patients with EGFR-mutated non-small cell lung cancer (NSCLC). Izalontamab brengitecan (Iza-bren; BL-B01D1) is a first... ...
